Trending at Lumira Ventures

LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome

Alyssia Watkin Portfolio News, LQT Therapeutics

Closing the gap between industry and academia to place patients directly at the center of research efforts.  LQT Therapeutics, a privately-held biopharmaceutical company advancing novel SGK1 kinase therapeutics, today announced that the project, “SILENCE-LQTS: SGK1 inhibition as a novel therapeutic …